Patents by Inventor Pierre Signore
Pierre Signore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050175657Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 2, 2004Publication date: August 11, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050169959Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 1, 2004Publication date: August 4, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050169958Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 1, 2004Publication date: August 4, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050165467Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.Type: ApplicationFiled: December 7, 2004Publication date: July 28, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
-
Publication number: 20050165488Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.Type: ApplicationFiled: December 7, 2004Publication date: July 28, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050158274Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 7, 2004Publication date: July 21, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050154454Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.Type: ApplicationFiled: December 7, 2004Publication date: July 14, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
-
Publication number: 20050154445Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.Type: ApplicationFiled: December 7, 2004Publication date: July 14, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
-
Publication number: 20050154453Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.Type: ApplicationFiled: November 29, 2004Publication date: July 14, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
-
Publication number: 20050149080Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.Type: ApplicationFiled: November 30, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050147643Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 7, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050147562Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 7, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050147599Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 7, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050149158Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.Type: ApplicationFiled: November 29, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050149173Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.Type: ApplicationFiled: November 10, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
-
Publication number: 20050149175Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.Type: ApplicationFiled: December 7, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
-
Publication number: 20050148512Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: November 10, 2004Publication date: July 7, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050143817Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.Type: ApplicationFiled: December 7, 2004Publication date: June 30, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
-
Publication number: 20050142163Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.Type: ApplicationFiled: December 1, 2004Publication date: June 30, 2005Applicant: Angiotech International AGInventors: William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins